Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models

Propranolol, a pleiotropic β-adrenergic blocker, has been anecdotally reported to reduce cerebral cavernous malformations (CCMs) in humans. However, propranolol has not been rigorously evaluated in animal models, nor has its mechanism of action in CCM been defined. We report that propranolol or its...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Clin Invest
Main Authors: Li, Wenqing, Shenkar, Robert, Detter, Mathew R., Moore, Thomas, Benavides, Christian, Lightle, Rhonda, Girard, Romuald, Hobson, Nicholas, Cao, Ying, Li, Yan, Griffin, Erin, Gallione, Carol, Zabramski, Joseph M., Ginsberg, Mark H., Marchuk, Douglas A., Awad, Issam A.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society for Clinical Investigation 2021
נושאים:
Concise Communication
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7843213/
https://ncbi.nlm.nih.gov/pubmed/33301422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI144893
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים